Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) | PAR 24 203

Opportunity Information: Apply for PAR 24 203

The NIH funding opportunity PAR 24-203, titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)," supports R01 research projects aimed at uncovering the biological mechanisms linking COVID-19 to Alzheimer disease and Alzheimer disease-related dementias (AD/ADRD). The core purpose is to move beyond broad clinical observations and instead use controlled experimental systems to explain how SARS-CoV-2 infection or COVID-19-related processes interact with brain pathways that matter for neurodegeneration, including how these interactions shape AD/ADRD-relevant pathology and cognitive outcomes. The emphasis is firmly on mechanistic, hypothesis-driven work rather than clinical trials, meaning applicants are expected to generate causal or pathway-level insight using experimental models rather than testing interventions in human participants.

The solicitation is designed for studies using animal models, cell culture systems, and/or human tissue-based models. A key requirement is that AD/ADRD biology must be integrated into the project in a meaningful way: either the model itself needs to incorporate AD/ADRD risk factors or pathology (for example, transgenic or knock-in AD models, genetic risk variants, or relevant aging and vascular features), or the study must include experimental readouts that directly assess AD/ADRD-relevant phenotypes. Those phenotypes could include classic neuropathologic features (such as amyloid, tau-related changes, neuroinflammation, synaptic and neuronal loss, vascular dysfunction, or blood-brain barrier alterations) and functionally relevant outcomes like cognition-linked measures in animal models or neuronal network function in advanced in vitro systems. The overall message is that COVID-19 is not being studied in isolation; it must be examined specifically in the context of mechanisms that intersect with AD/ADRD vulnerability, progression, or risk.

Within that framework, the NOFO highlights three main scientific directions. The first focuses on situations where AD/ADRD pathology is already present, asking applicants to determine how COVID-19 changes central nervous system pathology and cognitive outcomes in that setting. This line of work fits models that already display AD/ADRD-like features, and then tests how infection, viral proteins, inflammatory cascades, or downstream systemic effects of COVID-19 influence disease-relevant brain changes. The second direction targets prodromal or early-phase scenarios, where the model represents a pre-symptomatic stage and the question is whether COVID-19 accelerates the onset or pace of AD/ADRD pathology and cognitive deficits. This encourages studies that can capture early tipping points, including how an acute infection might produce lasting changes that shift trajectories toward neurodegeneration. The third direction addresses predisposition and risk, emphasizing mechanisms by which COVID-19 might increase future susceptibility to AD/ADRD or interact with established comorbidities and risk factors. In practice, that could mean dissecting cellular and molecular pathways that remain altered after infection, especially when layered onto risk contexts like aging biology, cardiometabolic disease, vascular dysfunction, genetic predisposition, or chronic inflammatory states, as long as the work stays mechanistic and model-based.

Administratively, this is a discretionary NIH grant opportunity using the R01 mechanism under the health funding category, with CFDA numbers 93.853 and 93.866. The opportunity lists an award ceiling of $500,000, and the original closing date provided is 2024-10-04. While the expected number of awards is not specified in the provided source data, the structure and constraints are clear: applicants should propose rigorous, non-clinical-trial research plans that can definitively connect COVID-19-related biological events to AD/ADRD-relevant neuropathology and outcomes.

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Domestic applicants can include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and additional categories labeled as "Other." The NOFO also explicitly calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and foreign organizations. In short, the funding is structured to invite a wide range of institutions to tackle a focused scientific problem: clarifying the mechanistic links between COVID-19 and AD/ADRD-relevant brain changes using experimental models and AD/ADRD-informed endpoints, without conducting clinical trials.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on 2024-04-12.
• Applicants must submit their applications by 2024-10-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 24 203

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: